Status:
RECRUITING
Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
Lead Sponsor:
Centre Leon Berard
Conditions:
Metastatic Pancreatic Cancer
Advanced Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patien...
Eligibility Criteria
Inclusion
- Male or female patient \> 18 years
- metastatic or advanced PDAC
- Patient pretreated with no more than one prior systemic chemotherapy for metastatic/advanced disease (radiotherapy is not counted as a line of therapy).
- Availability of an archival representative FFPE tumor sample from primary tumor (surgery or diagnostic biopsy) and/or from metastatic lesion if metastatic disease at initial diagnosis with associated pathology report from an archival tumor block.
- Life expectancy \> 3 months
- PS score 0 or 1.
Exclusion
- Curative therapy available
- Any condition contraindicated with blood sampling procedures required by the protocol.
- Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT05380414
Start Date
July 1 2022
End Date
September 1 2027
Last Update
July 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Léon Bérard
Lyon, France, 69373